Valganciсlovir in the treatment and prevention of cytomegalovirus infection


DOI: https://dx.doi.org/10.18565/epidem.2018.3.57-70

Shakhgildyan V.I.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
The paper deals with the clinical significance of cytomegalovirus (CMV) infection (CMVI) in different groups of patients (pregnant women, newborns, patients with hemoblastosis, organ transplant recipients, and HIV-infected patients), characterizes the main symptoms and syndromes typical for this disease, and presents algorithms for diagnosing active CMVI and CMV disease in pregnant women, newborns, and immunocompromised patients, by justifying the diagnostic and prognostic value of various concentrations of CMV DNA in biomaterials. The paper also describes approaches to treating acute and active CMVI in pregnant women, congenital CMVI, active and clinically apparent CMVI in organ transplant recipients and HIV-infected patients. The authors show the leading role of ganciclovir and valganciclovir in the treatment of manifest CMVI in adults and children, the role of valganciclovir as a drug of choice in the preventive therapy of organ transplant recipients and in that for active CMVI in post-transplant and in HIV-infected patients. They also give the results of studies on the efficacy and safety of valganciclovir when used in immunocompromised patients.
Keywords: CMV DNA, active CMV infection, cytomegalovirus (CMV) infection, valganciclovir
Read entire article

Literature

  1. Shakhgildyan V.I. [Diagnosis and treatment of cytomegalovirus infection in pregnant women and newborns]. Neonatologiya: novosti, mneniya, obucheniye 2017; (3): 70–82. ((In Russ.).
  2. Shakhgildyan V.I. [Cytomegalovirus infection. In: Yuschuk N.D., Vengerov U.Yu., eds. Infections Diseases: National Guidelines]. 2th ed. Moscow: GEOTAR-Media, 2018; 838–53. (In Russ.).
  3. Polin R.A., Spittser A.R. [Secretes of neonatology and perinatology. Translation from English under the general editorship of N.N. Volodin]. Moscow: BINOM, 2013. 624 p. (In Russ.).
  4. Walker S., Palma-Dias R., Wood E.M., Shekleton P., Giles L. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy and Childbirth 2013; (13): 96.
  5. Shakhgildyan V.I., Shipulina O.Yu., Silts V.V. [Diagnosis of cytomegalovirus infection in HIV-infected pregnant women and identification of risk factors for antenatal and intranatal fetal infection with cytomegalovirus]. Akusherstvo i ginecologiya 2005; (2): 24–9. (In Russ.).
  6. Kisteneva L.B. [The role of cytomegalovirus infection in formation of perinatal pathology]. Detskie infektsii 2013; (3): 44–7. (In Russ.).
  7. Balashov D.N. [Trends in the of cytomegalovirus infection in oncohematological patients]. Oncohematologiya 2013; (1): 46–51. (In Russ.).
  8. Han X.Y. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J. Clin. Microbiol. 2007; 45: 1126–32.
  9. O’Brien S., Ravandi F., Riehl T., Wierda W., Huang X., Tarrand J., et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving. Blood 2008; 111(4): 1816–9. DOI:10.1182/blood-2007-03-080010
  10. Kanvinde S., Bhargava P., Patwardhan S. Cytomegalovirus infection as a case of cytopenia after chemotherapy for hematology malignancies. Indian Pediatr. 2013; 50(2): 197–201.
  11. Prokopenko E.I., Cherbacova E.O., Vatazin A.V., Yankovoy A.G.. Pasov S.A.. Stepanov V.A.. Artemov D.V. [Results of valganciclovir prophylaxis prevention of cytomegalovirus infection in kidney transplant patients]. Klinicheskaya nefrologiya 2013; (5): 37–41. (In Russ.)
  12. Kotton C.N., Kumar D., Caliendo A.M., Asberg A, Chou S, Danziger-Isakov L, Humar A. Updated international consensus guidelines on the managament of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333–60.
  13. Gotie S.V., Moysyuk Y.G., eds. [Transplantology. Pharmacotherapy without errors. Guide for physicians]. Moscow: E-noto, 2014. 432 p. (In Russ.).
  14. Bartlett J.G., ed. The Johns Hopkins Hospital 2005-6 Guide to Medical Care of Patients With HIV Infection. 12 ed. Philadelphia, 2005; 308.
  15. Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Kanectri V.G. et al. [National Guidelines clinical observation and treatment of patients with HIV infection (Clinical Protocol)]. Èpidemiologiâi infekcionnye bolezni. Аktual’nye voprosy 2017; (6, prilozheniye): 80. (In Russ.).
  16. Shakhgildyan V.I. [Cytomegalovirus infection In: Pokrovsky V.V., ed. [Lectures on HIV]. Moscow: GEOTAR-Media, 2018; 348–82. (In Russ.).
  17. Yadrikhinskaya M.S., Shakhgildyan V.I., Safonova A.P., Shipulina O.Y. [Opportunistic infections in HIV-infected patients: structure and modern laboratory testing]. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2015; (1): 24–30. (In Russ.).
  18. YadrikhinskayaM.S., ShakhgildyanV.I., SafonovaA.P., ShipulinaO.Yu. [The role of molecular methods in diagnosis of opportunistic diseases in HIV-infected patients] Uralskiy meditskiy zhurnal 2016; 142(9): 103–9. (In Russ.).
  19. Zhukova L.I., Lebedev V.V., Gorodin V.N., Zotov S.V., Kovalevskaya O.I., Tchahoyan P.O. [Acute cytomegalovirus infection in adult HIV-negative patients]. Infektsionnye bolezni 2013; 11(1): 37–43. (In Russ.).
  20. Petrova G.V., Shakhgildyan V.I., Chistozvonova E.A., Pugacheva T.A., Turkot N.V., Egorova M.V., Sautenko O.Yu., Astasheva I.B., Romanova O.V., Kostycheva N.V., Grigoryeva T.E., Kulagina M.G. [Experience of using the antiviral therapy of generalized congenital cytomegalovirus infection]. Detskie infektsii 2016; 15(2): 61–8. DOI: 10.22627/2072-8107-2016-15-2-61-68 (In Russ.).
  21. Coll O., Benoist G., Ville Y., Weisman L.E., Botet F. Guidelines on CMV congenital infection (Recommendations and guidelines for perinatal practice). J. Prenatal Medicine 2009; (37): 433–5.
  22. Bonalumi S., Trapanese A., Santamaria A., D’Emidio L., Mobili L. Cytomegalovirus infection in pregnancy: review of the literature. J. Prenatal Medicine 2011; 5(1): 1–8.
  23. Shakhgildyan V.I, Shipulina O.Yu., Safonova A.P. et al. [Value of molecular techniques in the diagnosis of cytomegalovirus infection in HIV-infected patients In: Yakovlev A.A., Rahmanova A.G., ed. Almanac of infectious diseases]. Sankt-Peterburg: Nauchno-issledovatelskiy institut khimii Sankt-Peterburgskogo gosudarstvennogo universiteta, 2008: 241–9. (In Russ.).
  24. Shakhgildyan V.I, Dolgih T.I., Ermak T. N., Shipulina O.Yu. [Cytomegalovirus infection. In: Pokrovsky V.I., Tvorogova M.G., Shipulin G.A., ed. Laboratory diagnosis of infectious diseases]. Moscow: BINOM, 2013; 113–9. (In Russ.).
  25. Yadrikhinskaya M.S., Shakhgildyan V.I., Orlovskiy A.A., Yarovaya E.B., Shipulina O.Y. [The value of the quantity of cytomegalovirus in biological fluids for diagnosis of cytomegalovirus pneumonia in patients with HIV infection. Abstracts VI International Conference on HIV/AIDS in Eastern Europe and Central Asia]. Moscow, 2018; 103. http://www.eecaac2018.org/documents/docs/abstracts-eecaac2018 (In Russ.).
  26. Martin D.F., Sierra-Madero J., Walmsley S., Valganciclovir Study Group. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retin-itis. N. Engl. J. Med. 2002; 346: 1119–26.
  27. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 9.0; October, 2017). European AIDS Clinical Society. http://www.europeanaidsclinicalsociety.org.
  28. Bartlett J.G., Galant J., Fam P. [Clinical aspects of HIV-infection]. Moscow: R. Valent, 2012. 528 p. (In Russ.).
  29. van der Heiden P.L., Kaploe J.S., Barge R.M., Willemze R., Kroes A.C., Schippers E.F.. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic sterm cell transplantation recipeins. Bone Marrow Transplantant 2006; (37): 693–8. DOI: 10.1038/sj.bmt.1705311
  30. Humar A, Lebranchu Y, Vincenti F et al. The IMPACT Study: Valganciclovir Prophylaxis for Until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease. Abstract Book of American Transplant Congress. Boston, 2009; 201.
  31. Shakhgildyan V.I., Galina M.V., Shamshurina M.K., Silts V.V. [The first case of use of valgancyclovir use for the treatment of cytomegalovirus infection in a HIV-infected pregnant women]. Epidemiologiya i infektsionnye bolezni 2008; (3): 60–5. (In Russ.).
  32. Allice T., Busca A., Locatelli F., Falda M., Pittaluga F., Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J. Antimicrob. Chemother. 2009; 63(3): 600–8.
  33. Dektyareva A.V., Zubcov V.V., Nepsha O.S., Burmenskaya O.V.. Lachinyan V.L.. Donnikov A.E.. Milaya O.V.. Degtyarev D.N. [Experience with ganciclovir in the treatment of the generalized of cytomegalovirus infection]. Akusherstvo i ginekologiya 2012; (5): 103–8. (In Russ.).

For citations: Shakhgildyan V.I. Valganciсlovir in the treatment and prevention of cytomegalovirus infection. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2018; (3):57–70


About the Autors

For correspondence:
Vasily I. Shakhgildyan, Cand. Med. Sci., Senior Researcher, Specialized Research Department of AIDS Epidemiology and Prevention, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Address: 3a, Novogireevskaya St., Moscow 111123
Telephone: +7(495) 366-05-18
E-mail: vishakh@yandex.ru
Scopus Author ID: 6506922588
ORCID: https://org/0000-0002-8686-0487


Similar Articles

Back to Content

Бионика Медиа